LGALS3 and pulmonary fibrosis: Furthermore, at present, only TDI 139, a selective Gal-3 inhibitor, was investigated in phase Ia/Ib trials for safety, tolerability, pharmacokinetics, and biomarkers and in phase IIb trials in idiopathic pulmonary fibrosis patients (Table 1).